AstraZeneca-Bristol Myers Talks Spark Share Moves, Analyst Skepticism

AstraZeneca shares declined as much as 7 percent in London trading Monday after reports emerged of preliminary discussions about a merger with Bristol Myers Squibb. The potential combination, which sources described as exploratory and far from certain, could reach a combined value near 400 billion dollars and rank among the largest pharmaceutical deals on record. Neither company confirmed the talks, with AstraZeneca declining to comment and Bristol Myers Squibb offering no immediate response.

The market reaction reflected differing assessments of each firm's position. AstraZeneca, with a market capitalization around 264 billion dollars entering the session, has expanded steadily under chief executive Pascal Soriot since 2012 by building a pipeline of new medicines. The company aims for 80 billion dollars in annual sales by 2030. Bristol Myers Squibb, valued near 133 billion dollars, faces the loss of patent protection on several major products, including the blood thinner Eliquis and the cancer treatment Opdivo, which analysts expect to slow growth starting next year.

Analysts expressed surprise at the reported talks, noting that AstraZeneca's recent performance stems from internal development rather than large-scale acquisitions. Some questioned the strategic fit, given AstraZeneca's focus on oncology and the substantial overlap in cancer drug portfolios between the two firms. Regulatory review would likely examine that overlap closely, as antitrust authorities assess whether a combined entity would reduce competition in key therapeutic areas.

Bristol Myers Squibb shares rose about 6 percent in premarket trading in New York, while AstraZeneca's London-listed stock traded down 4.7 percent and weighed on the broader FTSE 100 index. A completed deal would expand AstraZeneca's U.S. footprint at a time when the company has already committed 50 billion dollars to research and manufacturing facilities there through 2030. It would also create one of the world's largest drugmakers by market value.

Observers pointed to the natural pressures of patent expiration as a driver for companies to seek scale through voluntary combinations. Bristol Myers Squibb must replace revenue from products losing exclusivity, while AstraZeneca has demonstrated the ability to advance its own candidates without external consolidation. Past large mergers in the sector have shown mixed results, often depending on whether integration preserves the research productivity that generated value in the first place.

Any transaction would face extended scrutiny from multiple regulators on both sides of the Atlantic. Such reviews can extend timelines and raise costs, sometimes deterring deals that might otherwise improve efficiency in drug development and distribution. Market participants will continue to watch for further signals from the companies involved, as details remain limited and the discussions could end without agreement.